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Abstract
Exposure to organophosphorus (OP) compounds can lead to serious neurological damage or death.
Following bioactivation by the liver cytochromes P450, the OP metabolites produced are potent
inhibitors of serine active-site enzymes including esterases, proteases and lipases. OPs may form
adducts on other cellular proteins. Blood cholinesterases (ChEs) have long served as biomarkers
of OP exposure in humans. However, the enzymatic assays used for biomonitoring OP exposures
have several drawbacks. A more useful approach will focus on multiple biomarkers and avoid
problems with the enzymatic activity assays. OP inhibitory effects result from a covalent bond
with the active-site serine of the target enzymes. The serine OP adducts become irreversible
following a process referred to as aging where one alkyl group dissociates over variable lengths of
time depending on the OP adduct. The OP-adducted enzyme then remains in circulation until it is
degraded, allowing for a longer window of detection compared with direct analysis of OPs or their
metabolites. Mass spectrometry (MS) provides a very sensitive method for identification of post-
translational protein modifications. MS analyses of the percentage adduction of the active-site
serine of biomarker proteins such as ChEs will eliminate the need for basal activity levels of the
individual and will provide for a more accurate determination of OP exposure. MS analysis of
biomarker proteins also provides information about the OP that has caused inhibition. Other useful
biomarker proteins include other serine hydrolases, albumin, tubulin and transferrin.
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1. Introduction and background
Humans can be subjected to an array of chemicals present in the environment, either by
occupational, accidental or intentional exposure. Organophosphates (OP) are toxic
compounds that include insecticides and chemical warfare agents, as well as antiwear agents
and naturally occurring OP toxins. OPs were discovered in the mid-19th century, but their
use in agriculture began following the World War II (Nigg and Knaak, 2000; Petroianu,
2010). OP insecticides, including azinphos methyl, chlorpyrifos and malathion, became
widely used in agriculture for the control of insect pests in the 1970s, when the
environmentally persistent organochlorine pesticides were banned. Their use in the US has
decreased by more than 60% since 1990, from 85 million pounds in 1990 to 33 million
pounds in 2007, with chlorpyrifos, malathion and acephate being the most used [US
Environmental Protection Agency (US EPA) 2007]. OPs are also used in residential settings
and other non-agricultural sectors, but to a much lower extent.
Although OPs insecticides are less inexpensive, less persistent in the environment and less
susceptible to pest resistance, they are more toxic to mammals than organochlorines. Their
primary mechanism of action is the inhibition of cholinesterases and other serine active-site
enzymes, causing a variety of adverse health effects. OP insecticides are involved in many
occupational poisoning cases, although accidental exposures in residential settings or
environmental contaminations also occur (Bolognesi, 2003). As a consequence, human
biological monitoring of these exposures has become essential. The term “biomonitoring”
was originally defined as “a systematic standardized collection of biological samples for the
measurement of a substance or its metabolites in body fluids (including blood and urine) of
exposed subjects with the objective to assess exposure and health risk” (Angerer et al. 2007;
Kapka-Skrzypczak et al. 2011). Biomonitoring of exposures involves the measurement of a
substance termed biomarker that can identify, track or monitor the state of the exposure and
other aspects of health (Kim et al. 2010). Biomarker identification and characterization is
critical for risk assessment and is an expanding area of research.
This review will focus on the detection of OP-adducted protein biomarkers as a more
sensitive and accurate assessment of OP exposure.
2. Biological effects of OP exposure
Biological effects of OP exposure include headaches, dizziness, salivation, lacrimation,
diarrhea, tremors, bradycardia, convulsions, coma and even death (Costa, 2006; Jokanovic et
al. 2011). These symptoms are a result of acetylcholine accumulation in synapses, causing
overstimulation. Thus, acetylcholinesterase, the enzyme that hydrolyzes acetylcholine, is the
main target for OPs. Other serine hydrolases are also inhibited by OPs (Casida and Quistad,
2004). Some OP compounds have been shown to induce a delayed neuropathy, known as
OP-induced delayed neuropathy (OPIDN), which manifests 1–3 weeks after exposure.
OPIDN is characterized by axonal degeneration of central and nervous peripheral systems
(Lotti and Moretto, 1999). OPIDN appears to result from inhibition and aging of a lipase/
esterase known as neuropathy target esterase (NTE) present in nerve tissue (Casida et al.
2008; Glynn, 1999; Johnson, 1969). The dose and duration of the exposure, as well as the
nature of the OP are factors that have been reported to modulate the effects induced by OP
exposure (Pope, 1999).
The inhibition of serine hydrolases by OPs is due to the formation of a covalent bond
between the alkyl phosphorus group of the OP and the hydroxyl residue of the active-site
serine. Although this phosphorylation is initially reversible, with time this complex can
undergo further metabolic reactions, known as “aging” (Masson et al. 2010). The aging
process consists in the loss of one of the two alkoxy groups of the OP attached to the
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phosphorus atom (Nigg and Knaak, 2000). Some OP adducts undergo further aging (e.g.
cresylphosphoserine), leaving a phosphate attached to the active-site serine (Fig.1)
(Schopfer et al. 2010). Once the adduct has aged, the binding to the active-site serine is
permanent.
The current treatment for OP exposures consists of the administration of the drug atropine,
which competes with acetylcholine for binding to muscarinic receptors at the synapses,
decreasing the effect of neurotransmitter accumulation. Atropine is administered in
combination with oximes, pralidoxime being the most commonly used. Oximes are
nucleophylic compounds that can reactivate cholinesterases before they undergo aging. The
efficacy of oximes in reactivation depends on the specific enzyme and the chemical structure
of the OP compound bound to the enzyme. It also depends on the delay in the administration
of the treatment. Some OP adducts such as the one generated by the nerve agent soman age
very rapidly. There is some controversy as to whether oximes are beneficial as a first
treatment for exposed subjects (Barelli et al. 2011; Eyer, 2003). For instance, a randomized
double-blind placebo-control trial published in 2009 concluded that pralidoxime
administration did not improve survival or reduce the need for intubation in subjects with
OP poisoning (Eddleston et al. 2009).
3. Biomonitoring OP exposures
Biological monitoring consists of assessing exposure and health risk in a workplace,
compared with a non-risk environment (Maroni et al. 2000). In 1949, after an agricultural
worker was killed by an acute exposure to parathion in Florida (United States), the Florida
citrus industry began biological monitoring of the workers (Griffiths et al. 1951; Nigg and
Knaak, 2000). Their purpose was to establish directions for the use of parathion by
correlating exposures to parathion with changes in blood cholinesterase levels. Currently,
Florida does not require cholinesterase monitoring of agricultural workers, although the
University of Florida has an ongoing cholinesterase monitoring program in which workers
can voluntarily enroll in it.
Originally, attention on biomonitoring OP exposures was focused on the cholinesterases
(ChEs) AChE and butyrylcholinesterase (BChE), the first OP targets described. OPs are
irreversible inhibitors of both ChEs, meaning that only new enzyme synthesis will restore
activity (Gutmann and Besser, 1990; Koelle and Gilman, 1946). Inhibition of blood ChEs
have long served to assess the physiological course of OP exposures, especially plasma
BChE activity since it is more sensitive to inhibition by some OPs than red blood cell (RBC)
AChE, and also recovers more rapidly following exposure. Inhibition of RBC AChE is a
good marker of neuronal AChE inhibition, and therefore, a good marker of the severity of
the OP intoxication. Taking into account that a 50% inhibition of neural AChE is necessary
for developing anti-cholinergic symptoms, early detection of exposures by monitoring blood
ChEs can allow interventions before severe symptoms occur. In addition, these
measurements also enable health care providers to follow recovery of the subject.
The standard method in use for biomonitoring OP exposures is the Ellman colorimetric
enzymatic assay, which uses acetylthiocholine to determine AChE activity or
butyrylthiocholine to determine BChE activity (Ellman et al. 1961). These assays are
accurate, reliable and inexpensive. Two other methods are also used to monitor ChE
activities, the end point delta pH method of Michel, which measures acetylcholine
breakdown measuringchanges in the pH, and the radioactive method of Johnson and Russell,
which extracts radiolabeled acetylcholine from its hydrolysis products (Wilson et al. 2005).
The data from these assays are not necessarily inter-convertible, and because the pH method
is slow, and the radioactive assay is expensive and uses radio isotopes, the Ellman assays
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have been the methods preferred. Unfortunately, these assays present some drawbacks. First
of all, pre-exposure activity determinations are required (Cocker et al. 2002; Garabrant et al.
2009). It is often difficult to obtain accurate baseline measurements for exposed individuals,
and there are some variations in activities of ChEs over time. These are not only
interpersonal variations, but also intrapersonal as a result of biological variability, certain
diseases and medications that may affect ChE levels (Lepage et al. 1985; Nigg and Knaak,
2000). Furthermore, the Ellman assays are not accurate at exposures causing 20% or less
ChE inhibition, and cannot elucidate which class of OP caused the inhibition (Sun and Lynn,
2007). In addition, the Ellman assays are not suitable for biomonitoring the full range of OP
exposures, since some OPs can cause adverse health effects with low levels of ChE
inhibition (Casida and Quistad, 2004; Pope, 1999). Despite these drawbacks, the Ellman
assays are currently the standard method for monitoring OP exposures, including
agricultural worker exposures in the states of California and Washington in the United
States.
An alternative approach involves the analysis of the dialkyl phosphate (DAP) and leaving
group metabolites in urine. In the late 1960s, Shafik and Enos initiated these analyses
(Shafik and Enos, 1969). DAP metabolites are produced during the hepatic and serum
metabolism of OPs, through bioactivation and/or detoxification pathways, and are
eliminated in the urine. A leaving group, specific for each OP, is also generated during this
metabolic process. Neither DAPs nor the leaving group are cholinesterase inhibitors. Thus,
the disadvantage of urinary DAP analysis is that they do not provide information about the
OP of exposure, since the metabolism of a given OP can release different DAPs, and same
DAPs can be released by different OPs (Sudakin and Stone, 2011). In addition, DAPs and
the leaving group are not only produced in vivo, it is widely known that they can be detected
in the environment. Once OPs are applied, they undergo degradation by a variety of
processes, including hydrolysis, photolysis and microbial degradation (Racke, 1992). There
are studies demonstrating the presence of DAPs or trichloropyridine (the leaving group
specific for chlorpyrifos hydrolysis) in food as well as contaminated surfaces (Eaton et al.
2008; Morgan et al. 2005; Sudakin and Stone, 2011). Thus, detection of urinary DAPs or the
corresponding leaving group cannot discriminate between OP exposure and direct
environmental exposure to non-toxic OP degradation products, resulting in possible
overestimation of the exposure (Egeghy et al. 2011; Morgan et al. 2011). Furthermore, their
half-lives are short, ranging between 24 and 48 h following exposure. On the other hand,
measurement of these urinary metabolites is less invasive and logistically simpler than the
ChE activity monitoring (Bravo et al. 2004; Cocker et al. 2002), providing incentive for use
of these analyses. Further studies are required to establish the relevance of urinary
metabolite analysis in assessing OP exposures. Nonetheless, DAP metabolites are common
for the majority of OP compounds, and while blood test for detecting OP exposures are still
under development, measurement of DAPs provides valuable information about chronic OP
exposures (Barr and Angerer, 2006; Barr et al. 2004).
4. Identification and characterization of protein biomarkers of OP exposure
There is increasing interest in the analysis of protein biomarkers of OP exposure since the
OP adducted proteins have longer half-lives than parent compounds or metabolites. Proteins
are modified only by the active pesticide or nerve agent and their breakdown products will
not react with target biomarker proteins. Proteins from the blood compartment fit the criteria
for useful biomarkers: they are biological proteins that can be analyzed to provide key
information about the health of the subject and the origin of the exposure, they can be
analyzed, they have relatively long half-lives, they are also relatively inexpensive to assay,
and they provide unequivocal information about the nature and level of OP exposure (Costa,
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1996; Henderson et al. 1989; Kim et al. 2010). Various blood proteins serve as biomarkers
of exposure, effect or susceptibility. This review focuses on biomarkers of OP exposure.
Serine hydrolases, especially ChEs, are classical biomarkers that have been studied and
monitored primarily because they contain a serine in the active site, and historically it was
thought that they were the only targets for OP compounds. However, it has been observed
that chronic low levels of certain OPs can cause neurotoxicity without significant ChE
inhibition, indicating that other proteins are also important OP targets (Ray and Richards,
2001; Richards et al. 1999). These other biomarker proteins may well serve as more
sensitive biomarkers than ChEs for some OPs.
The Ellman assays, the conventional method for monitoring OP exposures, are focused on
determining the remaining uninhibited cholinesterase activity. Unfortunately, as described in
the previous section, this method has several drawbacks. Thus, other approaches have been
developed, based on the detection of the inhibited enzyme. One of them involved the use of
fluoride ions to reactivate the inhibited enzyme. In this process, the original
phosphofluorides are regenerated and can be identified and quantified by gas
chromatography coupled with mass spectrometry (GC-MS) (Polhuijs et al. 1997). This
method provides identification of both the OP and extent of the exposure. However,
development of this approach is limited by the impossibility of reactivating aged
phosphorylated enzymes.
Following the development of approaches for monitoring OP-adducted enzymes, liquid
chromatography coupled with MS (LC-MS) and matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) MS have become important tools for biomonitoring OP-
adducted enzymes (John et al. 2008). They allow for the accurate and sensitive identification
of OP-inhibited proteins based on the change in mass of the adducted active-site peptides
following enzymatic digestion. Since serine esterases have a very stable adduct on their
active-site serines following the aging process, analysis by LC-MS or MALDI-TOF can
identify and characterize adducts by detecting the difference in the mass of the active-site
peptide. These OP-adducted enzymes remain in circulation for times that are dependent on
their half-lives, which are generally much longer than the half-lives of the parent OP
compound or its metabolites, providing a longer window for detection than the analysis of
urinary metabolites or free OPs in blood or urine. Further, it is possible to learn something
about the OP of exposure due to the mass differences between different adducts.
The proteomics techniques have also proved to be useful for the identification of new
biomarkers of OP exposure (Thompson et al. 2010).
4.1. Acetylcholinesterase and Butyrylcholinesterase
AChE (referred in the past as “true cholinesterase”, EC 3.1.1.7, accession # P22303), is a
tetrameric serine esterase glycoprotein, composed of 70 kDa subunits, and is found in the
terminal synapses of central and peripheral nerves, where it terminates synaptic
transmissions via hydrolysis of the neurotransmitter acetylcholine. As noted before, this
enzyme is also found on RBC membranes. AChE has been shown to be the primary target of
OP toxicants in mammals and insects (Koelle and Gilman, 1946).
BChE (also known as pseudocholinesterase or plasma cholinesterase, EC 3.1.1.8, accession
# P06276), is also a serine esterase glycoprotein, composed of four 85-kDa subunits, and is
present at high levels almost ubiquitously, but primarily in glial cells, liver and plasma.
BChE also hydrolyzes acetylcholine, as well as many other esters, including synthetic and
naturally occurring poisons. Therefore, it can act as a backup for AChE, as demonstrated
with the AChE knockout mouse (Duysen et al. 2001), even though acetylcholine hydrolysis
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is not the primary role of BChE. However, the physiological function of this enzyme is still
unclear.
The human body has approximately10 times more BChE than AChE (Manoharan et al.
2007). In vertebrates, both ChEs are inhibited by the alkaloid eserine, a property that
distinguishes them from non-specific esterases (Chatonnet and Lockridge, 1989). They exist
as soluble or membrane-bound polymers of catalytic subunits, with each subunit containing
an active-site serine (Nigg and Knaak, 2000). The most notable differences between these
two B-esterases are their substrate specificities, acetylcholine versus butyrylcholine, their
inhibition (AChE) or not (BChE) by excess substrate, and their expression during tissue
differentiation and development (Chatonnet and Lockridge, 1989). In addition, they show
different sensitivities for inhibition by different OP compounds (Aldridge, 1953).
The first compound known to inhibit ChEs, tetraethyl pyrophosphate, was synthesized in
1855 by Philipe de Clermont (Petroianu, 2010). Almost a century later, Langer and Krueger
synthesized alkyl fluorophosphate esters and described their toxicity, which led to an
increasing interest in OPs. These were the first OP compounds known to irreversibly inhibit
ChEs (Mackworth and Webb, 1948; Mazur and Bodansky, 1946). The most potent member
of this group, di-isopropyl fluorophosphate (DFP), has been extensively studied. In vitro and
in vivo studies on the mechanism of ChE inhibition by DFP revealed that once the OP binds
covalently to either ChE, the enzyme-inhibitor complex formed does not dissociate and the
inhibition of activity persists for many days (Mazur and Bodansky, 1946). These authors
also reported that in humans, plasma ChE was more sensitive to inhibition by DFP than
RBC or brain ChE, and that they have differential rates of restoration of activity. Another
interesting observation was that following low levels of DFP exposure, BChE was inhibited
in the absence of cholinergic symptoms. In the study of the mechanism of ChE inhibition by
OPs, an initial observation was that OPs and acetylcholine compete for binding to ChE,
indicating that OPs bind to the same active center of the enzyme (Augustinsson and
Nachmansohn, 1949). An observation by Aldridge was that different OPs have different
affinities for the ChEs, probably related to the composition of the alkyl groups attached to
the phosphorus, which modify their affinity for the ChEs, similar to the substrate preferences
of acetylcholine and butyrylcholine (Aldridge, 1953).
As noted above, inhibition of blood ChE (RBC AChE or plasma BChE) activities is
currently the standard method used for the biological monitoring of OP exposure. Thus,
ChEs are useful biomarkers of OP exposure since they are very sensitive to inhibition by
many OP compounds and are found in blood, a matrix that is easy to obtain and analyze.
One of the advantages of the enzymatic measurement of AChE versus BChE as a biomarker
of exposure is the half-life. RBC AChE has a 120 day life-span (≈33 day half-life; Mock et
al. 1999), although once it is inhibited, it has been shown that the recovery of AChE activity
occurs after approximately 80 days (Mason, 2000), suggesting that either exposed RBCs are
eliminated faster than unexposed RBCs or that some of the OP-inhibited AChE may be
reactivated. In contrast, BChE has an 11-day half-life in plasma (Mason, 2000; Ostergaard et
al. 1988). Therefore, RBC AChE enables the evaluation of exposure for a longer period of
time following exposure. On the other hand, the enzymatic measurement of BChE has some
advantages over AChE. Starting with the availability, there is more BChE than AChE in
blood. BChE is present as a soluble protein in plasma, while AChE is primarily found in the
RBC membrane. When assaying RBC ChE, there are difficulties in reproducibly removing
serum interferences from the RBCs and possible interference from the red cell hemoglobin
during the assay (Wilson et al. 2005). BChE can hydrolyze or scavenge a broader range of
OPs than AChE, probably due to differences in the geometries of their active-site gorges
(Masson et al. 2010).
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These drawbacks of the Ellman assay prompted research on MS-based assays focused on the
identification of OP-adducted proteins. AChE and BChE have been the most studied and
most used biomarkers for OP exposure, so they were the first examined by MS analysis.
Doorn and co-workers were the first to detect adducts with pure equine serum BChE
inhibited in vitro with isomalathion using MALDI-TOF (Doorn et al. 2001). A similar
approach using recombinant human AChE inhibited with various OPs was published in the
same year (Elhanany et al. 2001). However, as BChE is soluble and is abundant in plasma,
analysis of BChE adducts proved to be more useful. A year later, another method was
described that involved the use of liquid chromatography coupled with MS (LC/MS) to
analyze in vitro and in vivo nerve agent-inhibited BChE (Fidder et al. 2002). They suggested
that the same approach should work for OP pesticides and carbamates.
Following these first reports, a number of studies using similar approaches have been
published. The major focus of these studies has been on BChE (Li et al. 2008a; Li et al.
2010a; Liyasova et al. 2011; Noort et al. 2006; Sun and Lynn, 2007; Thompson et al. 2010).
The main limitation of these studies has been the difficulty in standardizing the method for
high-throughput analyses of exposures. The critical step is the purification of BChE from
plasma. All of the above studies used affinity chromatographic purifications that are time-
consuming and require relatively large sample volumes and the use of special resins. In
2007, highly sensitive capture methods using antibody-coupled magnetic beads, coupled to
LC-MS/MS were reported (Whiteaker et al. 2007). The use of immune-affinity purification
of BChE, coupled with MS, should overcome these disadvantages (Aryal et al. 2012; Kim et
al. 2010; Marsillach et al. 2011; Sporty et al. 2010). The rapid purification of BChE by
immunomagnetic-bead separation (IMS) requires smaller quantities of plasma and can be
easily automated. For immunoprecipitation protocols, it is important to identify a useful
antibody and magnetic beads that provide reproducible purifications with low background.
Furthermore, the IMS protocols are amenable for high-throughput robotic sample
processing. In all of the MS studies, once BChE has been purified, it is digested to peptide
fragments using proteolytic enzymes (trypsin, chymotrypsin, pepsin, etc.). The peptides are
then analyzed by MS (Fig. 2). The adducted active-site peptide is identified using a database
match.
4.2. Acylpeptide hydrolase
Acylpeptide hydrolase (APH, EC 3.4.19.1, accession # P13798) is a serine active-site
esterase/protease that cleaves N-acetylated peptides and most likely plays an important role
in intracellular protein turnover (Raphel et al. 1999). It is a tetrameric protein composed of
81-kDa subunits that is present in many tissues, including brain and liver. In circulation, it is
found in the cytosol of RBCs, where its role appeares to be degradation of proteins modified
by glycation or oxidation (Fujino et al. 2000). This enzyme becomes attached to the
membrane when the erythrocyte is oxidized (Fujino et al. 1998).
Although in 1987 it was reported that DFP inhibited APH activity (Kobayashi and Smith,
1987), the first evidence of APH as a non-cholinergic target for OP compounds came in
2000 (Richards et al. 2000), when it was shown that APH was a direct target for some OPs
and that it was more sensitive than AChE to OPs such as dichlorvos, both in vitro and in
vivo. Some years later, it was demonstrated that murine RBC APH could serve as a potential
biomarker of OP exposure (Quistad et al. 2005). In this study, it was shown that mouse APH
sensitivity to OP exposure was dependent on the specific OP. For example, as noted, APH
was more sensitive to dichlorvos compared with BChE or AChE; it was as sensitive as
BChE to tribufos; however, it was not sensitive to 10 other OPs tested. In addition, APH
inhibition could be detected after longer periods of time compared to BChE, an advantage
resulting from the long half-life of RBCs. It has also been suggested that APH may be
implicated in cognitive processes via a non-cholinergic pathway following exposure to OPs
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(Pancetti et al. 2007; Richards et al. 2000). More recently, in vitro OP-adducted human RBC
APH has been characterized by IMS followed by LC-MS/MS (Kim et al. 2010; Marsillach
et al. 2011), supporting the use of APH as a biomarker for OP exposure (Quistad et al.
2005). These studies made use of in vitro inhibited samples; there are still no MS data on
APH adducts from OP exposed individuals.
As mentioned, one of the advantages of using RBC APH as a biomarker of exposure is the
long half-life of RBCs (Mock et al. 1999), and the slow recovery of the activity following
exposure to OPs (Quistad et al. 2005). The 33 day half-life of RBCs allows for a longer
window in time for measuring the percentage of RBC APH active-site serine adducted by
OPs. One of the disadvantages is that APH in sensitive to some, but not all, OP compounds.
4.3. Albumin
Albumin, which has a 20 day half-life, is the most abundant protein found in plasma. It is a
67-kDa multifunctional monomer synthesized and secreted by the liver. Albumin possesses
esterase-like and aryl acylamidase activities but it does not have a catalytic active-site
serine. It is generally accepted that OPs cause irreversible inhibition of serine hydrolases by
binding to their active-site serines. Nevertheless, some in vitro and ex vivo studies have
already demonstrated covalent binding of OPs, such as soman and sarin, chlorpyrifos oxon,
dichlorvos, DFP and parathion, to albumin (Black et al. 1999; Li et al. 2007; Mourik and de
Jong, 1978; Sanger, 1963). Lockridge and co-workers were the first to detect OP adducts on
albumin in mice (Peeples et al. 2005; Schopfer et al. 2005) and exposed humans (Li et al.
2010b). They proposed albumin as a useful biomarker for OP exposure. The administration
of low doses of OPs to mice did not inhibit AChE activity but labeled albumin mainly on
tyrosine-411, the most reactive residue of albumin (Means and Wu, 1979; Schopfer et al.
2005). The detection of adducted albumin was carried out with tagged irreversible inhibitors
[fluorophosphonate (FP)-biotin] followed by MALDI-TOF analysis. The use of FP-biotin
had been already described as a powerful tool for labeling and identifying not only serine
hydrolases but any other proteins that interact with FPs (Liu et al. 1999). Labeling of serines
and additional tyrosines on albumin has also been described in vitro, but with much lower
reactivity (Ding et al. 2008). It has been argued that the possible role of OP binding by
albumin binding OPs would be to reduce the amount of OP available for reaction with serine
hydrolases (Peeples et al. 2005).
Albumin possesses several advantages as a biomarker of exposure, compared with the serine
hydrolases. The OP-tyrosine bond is more stable and does not age like OPs adducted to
active-site serines (Lockridge and Schopfer, 2010), allowing for a longer window of
exposure detection and a more reliable identification of the OP involved in the exposure.
Albumin is soluble in plasma and present in large quantities. In addition, oxime therapy does
not displace the adducted OP from albumin (Read et al. 2010), allowing for identification of
the OP of exposure after treating a patient. On the other hand, the rate of reaction of albumin
with OPs is much slower compared with BChE (Li et al. 2008b). Thus, albumin is a less
sensitive biomarker compared with BChE.
4.4. Carboxylesterase
Human carboxylesterase-1 (CES-1, EC 3.1.1.1, accession # 23141) is a trimeric 60-kDa
serine esterase involved in OP detoxication or metabolic activation of various drugs and
xenobiotics, as well as several environmental toxicants and carcinogens (Satoh and
Hosokawa, 1998). It belongs to a large multigene family. CES-1 is primarily expressed in
the endoplasmic reticulum and the cytosol of liver cells, but it is also found in lesser
amounts in many other tissues, such as intestine, kidney, lung, gonads, monocytes and
macrophages (Redinbo et al. 2003). CES catalyzes the hydrolysis of carboxylesters via a
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two-step process in which the active-site serine is acetylated and subsequently deacetylated
by the addition of water.
A half a century ago, Myers and Mendel (1949) reported that CES-1 (they called it
aliesterase) was targeted by tri-ortho-cresyl phosphate (ToCP) and DFP. Later, they obtained
results suggesting the preferential binding of some OPs to CES instead of ChEs, and
hypothesized that one of the functions of CES could be to bind OPs so there would be less
free OP to inhibit ChEs, thus modulating the negative effects of the OP exposure (Myers,
1952). The physiological evolution to protect against OP exposure is difficult to rationalize
since synthetic OPs have been used in only very recent times. Following the hypothesis
suggested by Myers, Su and co-workers administered 18 different OP insecticides to rats
and studied the differential inhibition of liver, plasma and brain CES-1, compared with
AChE. They observed that OPs have different potency as inhibitors of rat liver and plasma
CES-1 (liver CES-1 being more sensitive to OPs than plasma CES-1), indicating that OP
detoxication by CES-1 occurs predominantly in the liver, the site of OP bioactivation (Su et
al. 1971). In addition, rat liver CES-1 was more susceptible to OP inhibition than liver,
plasma and brain AChE, supporting the Myers’ hypothesis. It should also be noted that
CES-1 expression and activity can vary depending on the tissue and the organism analyzed
(Imai, 2006). However, the ability of CES-1 to detoxify OPs depends on the quantity of
enzyme (or the number of available binding sites in the enzyme) and the specific OP
compound (Chanda et al. 1997). Since CES-1 is a stoichiometric scavenger (each CES-1
molecule can bind only one OP molecule), CES-1 is a high affinity/low capacity scavenger
(Maxwell, 1992), in contrast to, for example, paraoxonase-1, a catalytic scavenger (Stevens
et al. 2008).
Monocyte CES-1 is found in the outer cell membrane as an “ectoenzyme”, where it can
readily interact with the extracellular environment. It has an amino acid content similar to
other esterases (Saboori and Newcombe, 1990). It has been demonstrated that OP
compounds also inhibit human monocyte CES-1 activity (Emmett et al. 1985; Lee and
Waters, 1977), providing another possible biomarker of exposure. FP-adducted murine
plasma CES-1 has also been reported (Peeples et al. 2005).
One of the main drawbacks of monocyte CES-1 as a biomarker of OP exposure is the
monocyte lifespan in circulation, which is only a few hours before they enter a tissue to
differentiate into macrophages. On monocytes, CES-1 is much more sensitive to some OPs
compared with AChE and BChE, and may be a useful biomarker if analyzed shortly after an
exposure.
4.5. Neuropathy Target Esterase
NTE (EC 3.1.1.5, accession # Q8IY17) is a 150-kDa integral membrane protein anchored to
the cytoplasmic face of the endoplasmic reticulum in both neurons and non-neural cells (Li
et al. 2003). Despite its high capacity for hydrolyzing esters, it has no homology with any
serine esterase or protease (Lush et al. 1998). NTE is primarily found in brain (especially in
large neurons) with a substantially lower presence in spinal cord and sciatic nerve. It travels
along axons by vesicular fast transport (Glynn et al. 1998). It is also found in non-neural
tissues including intestine, spleen, liver, thymus, kidney, or testis as well as in lymphocytes
(Dudek and Richardson, 1982; Glynn, 1999; Winrow et al. 2003).
In the 1930s, thousands of people in the United States were paralyzed by ingestion of
adulterated alcoholic ginger extracts, contaminated with ToCPs. This was the first example
of a large-scale OPIDN syndrome. In 1969, Martin Johnson reported the first evidence of in
vivo phosphorylation of a specific esterase of the nervous system (NTE) by OPs that
produced a delayed neurotoxic effect, later called OPIDN (Johnson, 1969). In his study with
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hens, Johnson determined that NTE was resistant to some non-neuropathic OPs like
paraoxon but sensitive to the neuropathic insecticide mipafox. Nonetheless, not all OPs that
covalently inhibited NTE were neuropathic. The essential event initiating OPIDN by
neuropathic OPs required the covalent phosphorylation of the NTE active-site serine,
followed by generation of negatively charged species by hydrolysis of one of the phosphoryl
ester bonds (Johnson, 1974). Johnson proposed that this charged group is responsible for the
metabolic disturbances that lead to axonal degeneration.
Human NTE is very similar to a Drosophila neuronal protein called Swiss cheese (Sws),
which is important in brain development and causes neurodegeneration when mutated (Lush
et al. 1998). By analogy, this may be a physiological role of human NTE, with an
involvement in neuronal-glial interaction during development, and in neurodegenerative
diseases. In fact, NTE is expressed in neurons of mouse embryos from their earliest
appearance in the developing nervous system (Moser et al. 2000); and the loss of NTE in
vivo in a Cre/loxP mouse, with specific deletion of NTE in neuronal tissues, contributes to
neurodegeneration characterized by vacuolization and neuronal loss (Akassoglou et al.
2004). Interestingly, the finding of an NTE-homologue in yeast suggests that NTE may have
functions beyond the nervous system (Lush et al. 1998). Studies with the recombinant
catalytic domain of NTE (known as NEST) indicated that lysolecithin (Quistad et al. 2003)
was a physiological substrate of NTE. According to these findings, NTE is also a
lysophospholipase with a possible contribution in phospholipid metabolism and membrane
remodeling, the inhibition of which may lead to OPIDN (van Tienhoven et al. 2002).
The presence of NTE in blood lymphocytes (Dudek and Richardson, 1982), and the finding
that its inhibition is correlated with NTE brain inhibition, poses NTE as another putative
biomarker of exposure to neuropathic OP compounds. Lymphocyte NTE inhibition can be
followed for up to 96 hours following OP exposure (Makhaeva et al. 2007).
4.6. Other biomarkers of exposure
The detection of OP adducts on the tyrosine-411 residue of albumin suggested that amino
acid residues other than serines may also be modified by OP exposure (Means and Wu,
1979; Schopfer et al. 2005). In the late 1960s, binding of DFP to tyrosine residues of papain
and bromelain was reported (Chaiken and Smith 1969; Murachi et al. 1965). Lockridge and
co-workers reported OP insecticide and nerve agent binding to tyrosine residues of bovine
alpha- and beta-tubulin (Grigoryan et al. 2008), and human and mouse transferrin (Li et al.
2009). In vivo detection of adducted tyrosines on brain tubulin from mice exposed to either
chlorpyrifos or chlorpyrifos oxon has also been reported (Jiang et al. 2010). The authors
suggest that adducts on tubulin could be responsible for neurotoxicity.
In addition to labeled tyrosines, adducted lysine residues have also been found in these and
other proteins where tyrosines were also labeled by OPs, as observed with albumin
(Lockridge and Schopfer 2010).
OP-adducted tyrosine and lysine residues in proteins with no active-site serine suggest that
other proteins are modified by OPs at residues other than the active-site serines. These OP
adducts may have biological implications in chronic exposures. Together with albumin,
other tyrosine- and lysine-adducted proteins may well serve as biomarkers for OP exposure,
although further studies are required to elucidate new proteins and sites of adduct formations
that may serve as useful biomarkers of OP exposure.
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Biomonitoring of OP exposures requires better and more accurate analyses than the ChE
activity measurements, especially since OPs have different affinities for biomarker proteins.
The assays that are currently being used have several drawbacks and cannot provide
information on the OP that generated the exposure. The Ellman assays need blood, the
collection of which is considered invasive and sometimes logistically difficult. In addition to
the post-exposure sample, a baseline sample is required in order to determine the percentage
of inhibited activity. The detection of urinary metabolites does not require an invasive
collection of the sample and can provide some information on the type of OP causing
exposure. However, the half-life of these metabolites is really short. In addition,
environmentally occurring OP-metabolites can also be detected in urine, causing a possible
overestimation of the exposure.
The focus on MS analyses of OP-adducted biomarker peptides represents significant
progress in the evaluation of OP exposures. MS has allowed development of new protocols
for identifying and characterizing biomarkers of OP exposure. MS has become a powerful
technique for discovering new biomarkers of exposure, specifically for the identification of
post-translational modifications of proteins (e.g., OP adducts). Although highly sensitive
and precise, MS approaches do have some drawbacks. The measurements can be difficult
and time consuming (Costa, 1996). They also need to be carried out in a stable laboratory-
based environment by well-trained technicians. The cost of MS instruments can be high. On
the other hand, adduct measurement by MS can identify intact parent compounds or
metabolites that are capable of forming covalent bonds with proteins, which represents a
great advantage. A baseline sample is not required with MS analyses, eliminating the blood
draw required for the baseline activity determination. In recent years, there have been
significant improvements in the practical application of MS (Clarke and Hoofnagle, 2011).
As a result, several clinical laboratories are beginning to use MS in routine assays, replacing
traditional immunoassay instruments. These improvements include obtaining analytical data
more rapidly with less expense, and an improvement in diagnostic accuracy. The
implementation of MS as a routine technique needs additional improvement, but its future is
promising.
There is much additional research that needs to be done in the area of biomarker
characterization. New biomarkers that are being discovered need to be further investigated
to ascertain whether or not they are better markers of exposure than the traditional ones. It is
also desirable to find the best panel of biomarkers that should be monitored in case of
exposure to an unknown OP. This is important since different OPs have different affinities
for different biomarker proteins and some do not undergo the aging process providing more
information about the OP associated with exposure. Overall, the identification and
quantification of biomarkers of OP exposure using MS analyses will provide methods with
increased accuracy and sensitivity. While modifications of biomarker proteins can provide
information about the nature and extent of an OP exposure, the mechanism of toxicity may
involve the modification of many other physiologically important proteins. Proteomic
approaches under development will also provide avenues for exploring the physiological
mechanisms of OP toxicity.
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Bioactivation, adduct formation and aging on BChE of the organophosphates chlorpyrifos,
diazinon, azinphos methyl and tri-ortho-cresyl phosphate.
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Mass spectra showing the identification of BChE adducted active-site chymotryptic peptide
by in vitro incubation with the active metabolite from tricresyl phosphate, cresyl saligenin
phosphate (adapted from Marsillach et al. 2011). The asterisk (*) indicates an added mass of
+ 80 Da that corresponds to a phosphate group covalently bound to the serine 198 of the
BChE active-site.
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